| Added by | chplanque |
|---|---|
| Group name | EquipeADV |
| Item Type | Journal Article |
| Title | Pregnane X-receptor promotes stem cell-mediated colon cancer relapse |
| Creator | Planque et al. |
| Author | Chris Planque |
| Author | Fatemeh Rajabi |
| Author | Fanny Grillet |
| Author | Pascal Finetti |
| Author | François Bertucci |
| Author | Meritxell Gironella |
| Author | Juan José Lozano |
| Author | Bertrand Beucher |
| Author | Julie Giraud |
| Author | Véronique Garambois |
| Author | Charles Vincent |
| Author | Daniel Brown |
| Author | Ludovic Caillo |
| Author | Jovana Kantar |
| Author | Michel Prudhomme |
| Author | Jérémie Ripoche |
| Author | Jean François Bourgaux |
| Author | Christophe Ginestier |
| Author | Antoni Castells |
| Author | Frédéric Hollande |
| Author | Julie Pannequin |
| Author | Jean Marc Pascussi |
| Abstract | Oncotarget. 2016 Aug 30;7(35):56558-56573. doi: 10.18632/oncotarget.10646. ABSTRACT Colorectal cancer lethality usually results from post-treatment relapse in the majority of stage II-IV patients, due to the enhanced resistance of Cancer Stem Cells (CSCs). Here, we show that the nuclear receptor Pregnane X Receptor (PXR, NR1I2), behaves as a key driver of CSC-mediated tumor recurrence. First, PXR is specifically expressed in CSCs, where it drives the expression of genes involved in self-renewal and chemoresistance. Clinically, high levels of PXR correlate with poor recurrence-free survival in a cohort of >200 stage II/III colorectal cancer patients treated with chemotherapy, for whom finding biomarkers of treatment outcome is an urgent clinical need. shRNA silencing of PXR increased the chemo-sensitivity of human colon CSCs, reduced their self-renewal and tumor-initiating potential, and drastically delayed tumor recurrence in mice following chemotherapy. This study uncovers PXR as a key factor for CSC self-renewal and chemoresistance and targeting PXR thus represents a promising strategy to minimize colorectal cancer relapse by selectively sensitizing CSCs to chemotherapy. PMID:27448961 | PMC:PMC5302934 | DOI:10.18632/oncotarget.10646 |
| Publication | Oncotarget |
| Date | 2016-07-25 00:00:00 |
| Language | en |
| DOI | 10.18632/oncotarget.10646 |
| URL | https://pubmed.ncbi.nlm.nih.gov/27448961/?utm_source=Firefox&utm_medium=rss&utm_campaign=pubmed-2&utm_content=16WqI68KDOBEDOCNE1P3RxYQYPTwTutpbvUaDhoUuYPuJd459j&fc=20250120064306&ff=20250120064533&v=2.18.0.post9+e462414 |
| Tags | first, original |
| Date Added | 2025/01/20 - 14:26:35 |
| Date Modified | 2025/01/20 - 15:20:04 |
| Notes and Attachments | (Attachment) |
Institut de Recherche en Cancérologie de
